查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1818084

全球製藥製造自動化市場：預測至 2032 年—按組件、自動化模式、應用、最終用戶和地區進行分析

Automation in Pharmaceutical Manufacturing Market Forecasts to 2032 - Global Analysis By Component (Hardware, Software, and Services), Mode of Automation (Semi-Automatic Systems, and Fully Automatic Systems), Application, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的數據，全球製藥製造自動化市場預計在 2025 年達到 135 億美元，到 2032 年將達到 287 億美元，預測期內的複合年成長率為 11.3%。

製藥生產自動化涉及機器人技術、製程控制系統和數據分析的整合，以簡化藥品、疫苗和生技藥品的生產。配方、填充、包裝和品管的自動化可提高準確性、一致性和法規遵循。自動化減少了人為干預，最大限度地降低了污染和操作失誤的風險。它加快了生產週期，同時確保了產品的高品質。由於藥品需求不斷成長、監管審查日益嚴格以及全球健康挑戰日益嚴峻，對可擴展且高效的生產方法的需求推動了市場的發展。

對高效藥品生產的需求不斷增加

製藥業面臨著巨大的壓力，需要在管理複雜的生產流程的同時縮短新治療方法的上市時間。自動化能夠直接解決這個問題，它能夠提高生產線的產量，最大限度地減少人為錯誤，並確保批次間的一致性。此外，自動化還能幫助製造商最佳化資源利用率，降低長期營運成本。在競爭和經濟壓力的驅動下，對效率的不懈追求是投資自動化系統（從機器人流程自動化到整合控制系統）的根本催化劑。

自動化設備投入大

進入和拓展市場的一個重大障礙是自動化基礎設施所需的巨額資本支出。這不僅包括用於複雜機器人、製造執行系統 (MES) 和專用硬體的初始投入，還包括系統整合、檢驗和員工培訓的附加成本。此外，整體擁有成本也帶來了巨大的財務挑戰，尤其對中小型企業 (SME) 而言。如此高的投資標準會減慢投資報酬率 (ROI) 的計算速度，並需要長期的策略規劃，這限制了各級製藥企業的廣泛採用。

擴大生物製藥生產

生物製藥產業（包括生技藥品、單株抗體以及細胞和基因療法）的快速發展為自動化帶來了巨大的機會。這些複雜的產品需要嚴格的環境控制、精確的過程參數管理以及理想情況下由自動化封閉式系統管理的無菌製程條件。自動化確保了這些精細工藝所需的高保真度和可重複性。此外，靈活的模組化自動化解決方案可以有效緩解生物生產固有的可擴展性挑戰，從而為自動化供應商開闢新的高價值細分市場。

互聯系統中的網路安全威脅

隨著製藥製造業擁抱工業4.0，操作技術(OT) 與資訊科技 (IT) 的整合也帶來了網路攻擊的風險。高效互聯的自動化系統雖然容易受到攻擊，但可能導致智慧財產權被盜、營運中斷或程式參數被嚴重篡改，從而危及藥品的安全性和有效性。成功的攻擊不僅會直接威脅患者健康，還可能導致嚴重的監管違規行為和聲譽受損。因此，網路威脅的複雜性已成為製藥業數位轉型面臨的重大挑戰。

COVID-19的影響：

新冠疫情是製藥自動化市場的主要催化劑，暴露了全球供應鏈中的關鍵漏洞，並凸顯了對敏捷且富有韌性的製造能力的迫切需求。疫苗和治療藥物的空前需求加速了自動化的應用，以便在保持設施內社交距離的同時快速擴大生產通訊協定。這場危機凸顯了自動化系統在確保業務永續營運的重要性，迫使許多製造商加快數位化和自動化策略，以確保其營運在未來能夠抵禦類似的中斷。

預計硬體部分將成為預測期內最大的部分

預計硬體部分將在預測期內佔據最大的市場佔有率，因為它是任何自動化裝置的物理支柱。此部分包括機械臂、自動化工作單元、感測器、控制器和組裝等關鍵組件。這些有形資產需要大量的資本支出，是工廠車間自動化流程的關鍵推動因素。由於這些核心組件持續需要建立初始自動化功能，再加上其高成本軟體和服務，這些因素鞏固了硬體在整體市場收益中的主導地位。

預計在預測期內，品管和法規遵循部分將以最高的複合年成長率成長。

預計品管和法規遵從領域將在預測期內實現最高成長率，這得益於製藥業必須嚴格遵守美國食品藥物管理局 (FDA) 和歐洲藥品管理局 (EMA) 等機構制定的《藥品生產品質管理規範》(GMP) 指南。在這一領域，透過機器視覺檢測和自動取樣系統等技術實現的自動化，可顯著減少人為錯誤，並提供可靠且數據豐富的審核追蹤。此外，藥品日益複雜，人工品質檢查已難以滿足需求，這推動了對先進自動化合規解決方案的需求，以確保患者安全並簡化監管核准。

佔比最大的地區：

預計北美將在預測期內佔據最大的市場佔有率。這種主導地位得益於其成熟的製藥業、主要市場參與者的集中以及早期的技術採用。此外，美國食品藥物管理局 (FDA) 實施的嚴格法律規範也是推動製造商採用先進流程來確保品質的主要促進因素。該地區擁有雄厚的財力，能夠投資於高成本的自動化技術，並專注於複雜的生技藥品研究，這些優勢使其牢牢佔據了市場收益的領先地位。

複合年成長率最高的地區：

預計亞太地區在預測期內的複合年成長率最高。這項加速成長的動力源自於印度和中國等國家不斷擴大的製藥生產足跡，這些國家是國際原料藥和學名藥的製造地。該地區各國政府正積極透過「工業4.0」和「印度製造」等舉措推動工業自動化。此外，跨國公司尋求經濟高效的生產替代方案的投資不斷增加，加上國內對高品質藥品的需求不斷成長，正在推動全部區域製造設施的快速現代化和自動化。

成分

  • 硬體
  • 軟體
  • 服務

免費客製化服務

此報告的訂閱者可以選擇以下免費自訂選項之一：

  • 公司簡介
    • 對最多三家其他公司進行全面分析
    • 主要企業的SWOT分析（最多3家公司）
  • 區域分類
    • 根據客戶興趣對主要國家進行的市場估計、預測和複合年成長率（註：基於可行性檢查）
  • 競爭基準化分析
    • 根據產品系列、地理分佈和策略聯盟對主要企業基準化分析

目錄

第1章執行摘要

第 2 章 簡介

  • 概述
  • 相關利益者
  • 分析範圍
  • 分析方法
    • 資料探勘
    • 數據分析
    • 數據檢驗
    • 分析方法
  • 分析材料
    • 主要研究資料
    • 二手研究資訊來源
    • 先決條件

第3章市場走勢分析

  • 驅動程式
  • 抑制因素
  • 市場機遇
  • 威脅
  • 應用分析
  • 最終用戶分析
  • 新興市場
  • COVID-19的感染疾病

第4章 波特五力分析

  • 供應商的議價能力
  • 買方議價能力
  • 替代產品的威脅
  • 新參與企業的威脅
  • 企業之間的競爭

5. 全球製藥製造自動化市場（按組件）

  • 硬體
    • 機器人
    • 控制系統
    • 感測器和測量設備
    • 驅動馬達
    • 其他硬體
  • 軟體
    • 製造執行系統（MES）
    • 實驗室資訊管理系統（LIMS）
    • 企業資源計劃（ERP）
    • 分散式控制系統 (DCS) 軟體
    • 流程分析技術 (PAT) 軟體
    • 工廠資產管理 (PAM) 軟體
  • 服務
    • 整合和諮詢服務
    • 維護和支援服務

6. 全球製藥製造自動化市場（依自動化模式）

  • 半自動系統
  • 全自動系統

7. 全球製藥製造自動化市場（按應用）

  • 藥物研發
  • 臨床試驗
  • 生產加工
    • 活性藥物成分 (API) 製造
    • 混合、填充和精加工
    • 包裝和標籤
  • 品管/法規遵從
  • 物流和庫存管理

8. 全球製藥製造自動化市場（依最終用戶）

  • 製藥公司
  • 生技公司
  • CDMO/CMO（合約開發/製造組織）
  • 研究和學術機構

9. 全球製藥製造自動化市場（按地區）

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙
    • 其他歐洲國家
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 紐西蘭
    • 韓國
    • 其他亞太地區
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地區
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 卡達
    • 南非
    • 其他中東和非洲地區

第10章：主要趨勢

  • 合約、商業夥伴關係和合資企業
  • 企業合併（M&A）
  • 新產品發布
  • 業務擴展
  • 其他關鍵策略

第11章 公司概況

  • Siemens
  • Rockwell Automation
  • KUKA
  • Becton Dickinson and Company
  • Capsa Healthcare
  • Omnicell
  • Baxter International
  • Yuyama
  • ScriptPro
  • Swisslog Healthcare
  • SYNTEGON
  • IMA Group
  • GEA Group
  • FANUC
  • Themis Automation
  • Turck
  • Bausch+Strobel
  • Sartorius
Product Code: SMRC31047

According to Stratistics MRC, the Global Automation in Pharmaceutical Manufacturing Market is accounted for $13.5 billion in 2025 and is expected to reach $28.7 billion by 2032 growing at a CAGR of 11.3% during the forecast period. Automation in pharmaceutical manufacturing involves integrating robotics, process control systems, and data analytics to streamline production of medicines, vaccines, and biologics. It enhances precision, consistency, and regulatory compliance by automating formulation, filling, packaging, and quality control. Automation reduces human intervention, minimizing contamination risks and operational errors. It accelerates production cycles while ensuring high product quality. The market grows due to increasing demand for pharmaceuticals, regulatory scrutiny, and the need for scalable, efficient production methods amid rising global health challenges.

Market Dynamics:

Driver:

Increasing demand for efficient drug production

The industry faces immense pressure to reduce time-to-market for new therapies while managing complex production workflows. Automation directly addresses this by enhancing production line throughput, minimizing human error, and ensuring batch-to-batch consistency. Furthermore, it enables manufacturers to optimize resource utilization and lower long-term operational costs. This relentless pursuit of efficiency, driven by competitive and economic pressures, is a fundamental catalyst for investing in automated systems, from robotic process automation to integrated control systems.

Restraint:

High investment in automation equipment

A significant barrier to market entry and expansion is the substantial capital expenditure required for automation infrastructure. This includes not only the initial outlay for sophisticated robotics, manufacturing execution systems (MES), and specialized hardware but also the ancillary costs for system integration, validation, and employee training. Moreover, the total cost of ownership presents a considerable financial challenge, particularly for small and mid-sized enterprises (SMEs). This high investment threshold can delay ROI calculations and necessitates long-term strategic planning, thereby restraining widespread adoption across all tiers of pharmaceutical manufacturers.

Opportunity:

Expansion of biopharmaceutical production

The rapid growth of the biopharmaceutical sector, encompassing biologics, monoclonal antibodies, and cell and gene therapies, presents a substantial opportunity for automation. These complex products require stringent environmental controls, precise process parameter management, and aseptic processing conditions that are ideally managed by automated and closed systems. Automation ensures the high fidelity and reproducibility necessary for these sensitive processes. Additionally, the scalability challenges inherent in bioproduction can be effectively mitigated through flexible and modular automation solutions, opening a new and high-value market segment for automation vendors.

Threat:

Cybersecurity threats in connected systems

As pharmaceutical manufacturing embraces Industry 4.0, the convergence of operational technology (OT) with information technology (IT) creates vulnerabilities to cyber-attacks. Connected automation systems, while efficient, are potential targets for breaches that could lead to intellectual property theft, operational shutdown, or catastrophic manipulation of process parameters compromising drug safety and efficacy. A successful attack not only poses a direct threat to patient health but also risks severe regulatory non-compliance and reputational damage. Consequently, the evolving sophistication of cyber threats remains a critical concern for the industry's digital transformation.

Covid-19 Impact:

The COVID-19 pandemic acted as a profound catalyst for the pharmaceutical automation market. It exposed critical vulnerabilities in global supply chains and highlighted the urgent need for agile and resilient manufacturing capabilities. The unprecedented demand for vaccines and therapeutics accelerated the adoption of automation to rapidly scale up production while maintaining social distancing protocols in facilities. This crisis underscored the value of automated systems in ensuring business continuity, thereby compelling many manufacturers to fast-track their digitalization and automation strategies to future-proof their operations against similar disruptions.

The hardware segment is expected to be the largest during the forecast period

The hardware segment is expected to account for the largest market share during the forecast period due to its fundamental role as the physical backbone of any automation setup. This segment includes essential components such as robotics arms, automated workcells, sensors, controllers, and assembly lines. These tangible assets require significant capital investment and are the primary enablers of automated processes on the factory floor. The continued necessity for these core components to establish initial automation capabilities, coupled with their high cost relative to software and services, solidifies hardware's dominant position in the overall market revenue.

The quality control and regulatory compliance segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the quality control and regulatory compliance segment is predicted to witness the highest growth rate. This is driven by the pharmaceutical industry's non-negotiable requirement to adhere to stringent Good Manufacturing Practice (GMP) guidelines set by agencies like the FDA and EMA. Automation in this segment, through technologies like machine vision for inspection and automated sampling systems, drastically reduces human error and provides robust, data-rich audit trails. Moreover, the increasing complexity of drug products makes manual quality checks insufficient, thereby fueling the demand for advanced, automated compliance solutions to ensure patient safety and streamline regulatory approvals.

Region with largest share:

During the forecast period, the North America region is expected to hold the largest market share. This dominance is attributed to the presence of a well-established pharmaceutical industry, a high concentration of leading market players, and early technological adoption. Furthermore, the stringent regulatory framework enforced by the U.S. FDA compelling manufacturers to implement advanced processes for quality assurance acts as a key driver. The region's robust financial capacity to invest in high-cost automation technologies and a strong focus on researching complex biologics solidify its position as the revenue leader in this market.

Region with highest CAGR:

Over the forecast period, the Asia Pacific region is anticipated to exhibit the highest CAGR. This accelerated growth is fueled by the expanding pharmaceutical manufacturing footprint in countries like India and China, which are major global hubs for API and generic drug production. Governments in the region are actively promoting industrial automation through initiatives like "Industry 4.0" and "Make in India." Additionally, increasing investments from multinational corporations seeking cost-effective production alternatives, coupled with rising domestic demand for high-quality medicines, are driving the rapid modernization and automation of manufacturing facilities across the region.

Key players in the market

Some of the key players in Automation in Pharmaceutical Manufacturing Market include Siemens, Rockwell Automation, KUKA, Becton Dickinson and Company, Capsa Healthcare, Omnicell, Baxter International, Yuyama, ScriptPro, Swisslog Healthcare, SYNTEGON, IMA Group, GEA Group, FANUC, Themis Automation, Turck, Bausch+Strobel, and Sartorius.

Key Developments:

In July 2025, Capsa Healthcare acquired BlueBin, integrating predictive analytics and Kanban-based supply chain systems to enhance clinical supply management.

In June 2025, Pharbaco achieved GMP-EU compliance by implementing advanced automation and energy-efficient cleanroom solutions, utilizing FactoryTalk(R) Historian for environmental data analysis.

In February 2025, Siemens announced its Xcelerator Smart Lab Ecosystem, which revolutionizes lab and cleanroom design with modular, plug-and-play infrastructure. This solution can accelerate lab design by up to 80% while ensuring compliance with pharmaceutical standards.

In January 2025, BD and Biosero announced a collaboration to integrate robotic arms with BD's flow cytometry instruments, aiming to accelerate drug discovery and development.

Components:

  • Hardware
  • Software
  • Services

Mode of Automations Covered:

  • Semi-Automatic Systems
  • Fully Automatic Systems

Applications Covered:

  • Drug Discovery and Development
  • Clinical Trials
  • Production and Processing
  • Quality Control and Regulatory Compliance
  • Logistics and Inventory Management

End Users Covered:

  • Pharmaceutical Companies
  • Biotechnology Companies
  • Contract Development & Manufacturing Organizations (CDMOs / CMOs)
  • Research and Academic Institutions

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2024, 2025, 2026, 2028, and 2032
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Application Analysis
  • 3.7 End User Analysis
  • 3.8 Emerging Markets
  • 3.9 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Automation in Pharmaceutical Manufacturing Market, By Component

  • 5.1 Introduction
  • 5.2 Hardware
    • 5.2.1 Robots
    • 5.2.2 Control Systems
    • 5.2.3 Sensors and Instrumentation
    • 5.2.4 Drives and Motors
    • 5.2.5 Other Hardware
  • 5.3 Software
    • 5.3.1 Manufacturing Execution System (MES)
    • 5.3.2 Laboratory Information Management System (LIMS)
    • 5.3.3 Enterprise Resource Planning (ERP)
    • 5.3.4 Distributed Control System (DCS) Software
    • 5.3.5 Process Analytical Technology (PAT) Software
    • 5.3.6 Plant Asset Management (PAM) Software
  • 5.4 Services
    • 5.4.1 Integration & Consulting Services
    • 5.4.2 Maintenance & Support Services

6 Global Automation in Pharmaceutical Manufacturing Market, By Mode of Automation

  • 6.1 Introduction
  • 6.2 Semi-Automatic Systems
  • 6.3 Fully Automatic Systems

7 Global Automation in Pharmaceutical Manufacturing Market, By Application

  • 7.1 Introduction
  • 7.2 Drug Discovery and Development
  • 7.3 Clinical Trials
  • 7.4 Production and Processing
    • 7.4.1 Active Pharmaceutical Ingredients (API) Manufacturing
    • 7.4.2 Formulation and Fill-Finish
    • 7.4.3 Packaging and Labeling
  • 7.5 Quality Control and Regulatory Compliance
  • 7.6 Logistics and Inventory Management

8 Global Automation in Pharmaceutical Manufacturing Market, By End User

  • 8.1 Introduction
  • 8.2 Pharmaceutical Companies
  • 8.3 Biotechnology Companies
  • 8.4 Contract Development & Manufacturing Organizations (CDMOs / CMOs)
  • 8.5 Research and Academic Institutions

9 Global Automation in Pharmaceutical Manufacturing Market, By Geography

  • 9.1 Introduction
  • 9.2 North America
    • 9.2.1 US
    • 9.2.2 Canada
    • 9.2.3 Mexico
  • 9.3 Europe
    • 9.3.1 Germany
    • 9.3.2 UK
    • 9.3.3 Italy
    • 9.3.4 France
    • 9.3.5 Spain
    • 9.3.6 Rest of Europe
  • 9.4 Asia Pacific
    • 9.4.1 Japan
    • 9.4.2 China
    • 9.4.3 India
    • 9.4.4 Australia
    • 9.4.5 New Zealand
    • 9.4.6 South Korea
    • 9.4.7 Rest of Asia Pacific
  • 9.5 South America
    • 9.5.1 Argentina
    • 9.5.2 Brazil
    • 9.5.3 Chile
    • 9.5.4 Rest of South America
  • 9.6 Middle East & Africa
    • 9.6.1 Saudi Arabia
    • 9.6.2 UAE
    • 9.6.3 Qatar
    • 9.6.4 South Africa
    • 9.6.5 Rest of Middle East & Africa

10 Key Developments

  • 10.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 10.2 Acquisitions & Mergers
  • 10.3 New Product Launch
  • 10.4 Expansions
  • 10.5 Other Key Strategies

11 Company Profiling

  • 11.1 Siemens
  • 11.2 Rockwell Automation
  • 11.3 KUKA
  • 11.4 Becton Dickinson and Company
  • 11.5 Capsa Healthcare
  • 11.6 Omnicell
  • 11.7 Baxter International
  • 11.8 Yuyama
  • 11.9 ScriptPro
  • 11.10 Swisslog Healthcare
  • 11.11 SYNTEGON
  • 11.12 IMA Group
  • 11.13 GEA Group
  • 11.14 FANUC
  • 11.15 Themis Automation
  • 11.16 Turck
  • 11.17 Bausch+Strobel
  • 11.18 Sartorius

List of Tables

  • Table 1 Global Automation in Pharmaceutical Manufacturing Market Outlook, By Region (2024-2032) ($MN)
  • Table 2 Global Automation in Pharmaceutical Manufacturing Market Outlook, By Component (2024-2032) ($MN)
  • Table 3 Global Automation in Pharmaceutical Manufacturing Market Outlook, By Hardware (2024-2032) ($MN)
  • Table 4 Global Automation in Pharmaceutical Manufacturing Market Outlook, By Robots (2024-2032) ($MN)
  • Table 5 Global Automation in Pharmaceutical Manufacturing Market Outlook, By Control Systems (2024-2032) ($MN)
  • Table 6 Global Automation in Pharmaceutical Manufacturing Market Outlook, By Sensors and Instrumentation (2024-2032) ($MN)
  • Table 7 Global Automation in Pharmaceutical Manufacturing Market Outlook, By Drives and Motors (2024-2032) ($MN)
  • Table 8 Global Automation in Pharmaceutical Manufacturing Market Outlook, By Other Hardware (2024-2032) ($MN)
  • Table 9 Global Automation in Pharmaceutical Manufacturing Market Outlook, By Software (2024-2032) ($MN)
  • Table 10 Global Automation in Pharmaceutical Manufacturing Market Outlook, By Manufacturing Execution System (MES) (2024-2032) ($MN)
  • Table 11 Global Automation in Pharmaceutical Manufacturing Market Outlook, By Laboratory Information Management System (LIMS) (2024-2032) ($MN)
  • Table 12 Global Automation in Pharmaceutical Manufacturing Market Outlook, By Enterprise Resource Planning (ERP) (2024-2032) ($MN)
  • Table 13 Global Automation in Pharmaceutical Manufacturing Market Outlook, By Distributed Control System (DCS) Software (2024-2032) ($MN)
  • Table 14 Global Automation in Pharmaceutical Manufacturing Market Outlook, By Process Analytical Technology (PAT) Software (2024-2032) ($MN)
  • Table 15 Global Automation in Pharmaceutical Manufacturing Market Outlook, By Plant Asset Management (PAM) Software (2024-2032) ($MN)
  • Table 16 Global Automation in Pharmaceutical Manufacturing Market Outlook, By Services (2024-2032) ($MN)
  • Table 17 Global Automation in Pharmaceutical Manufacturing Market Outlook, By Integration & Consulting Services (2024-2032) ($MN)
  • Table 18 Global Automation in Pharmaceutical Manufacturing Market Outlook, By Maintenance & Support Services (2024-2032) ($MN)
  • Table 19 Global Automation in Pharmaceutical Manufacturing Market Outlook, By Mode of Automation (2024-2032) ($MN)
  • Table 20 Global Automation in Pharmaceutical Manufacturing Market Outlook, By Semi-Automatic Systems (2024-2032) ($MN)
  • Table 21 Global Automation in Pharmaceutical Manufacturing Market Outlook, By Fully Automatic Systems (2024-2032) ($MN)
  • Table 22 Global Automation in Pharmaceutical Manufacturing Market Outlook, By Application (2024-2032) ($MN)
  • Table 23 Global Automation in Pharmaceutical Manufacturing Market Outlook, By Drug Discovery and Development (2024-2032) ($MN)
  • Table 24 Global Automation in Pharmaceutical Manufacturing Market Outlook, By Clinical Trials (2024-2032) ($MN)
  • Table 25 Global Automation in Pharmaceutical Manufacturing Market Outlook, By Production and Processing (2024-2032) ($MN)
  • Table 26 Global Automation in Pharmaceutical Manufacturing Market Outlook, By Active Pharmaceutical Ingredients (API) Manufacturing (2024-2032) ($MN)
  • Table 27 Global Automation in Pharmaceutical Manufacturing Market Outlook, By Formulation and Fill-Finish (2024-2032) ($MN)
  • Table 28 Global Automation in Pharmaceutical Manufacturing Market Outlook, By Packaging and Labeling (2024-2032) ($MN)
  • Table 29 Global Automation in Pharmaceutical Manufacturing Market Outlook, By Quality Control and Regulatory Compliance (2024-2032) ($MN)
  • Table 30 Global Automation in Pharmaceutical Manufacturing Market Outlook, By Logistics and Inventory Management (2024-2032) ($MN)
  • Table 31 Global Automation in Pharmaceutical Manufacturing Market Outlook, By End User (2024-2032) ($MN)
  • Table 32 Global Automation in Pharmaceutical Manufacturing Market Outlook, By Pharmaceutical Companies (2024-2032) ($MN)
  • Table 33 Global Automation in Pharmaceutical Manufacturing Market Outlook, By Biotechnology Companies (2024-2032) ($MN)
  • Table 34 Global Automation in Pharmaceutical Manufacturing Market Outlook, By Contract Development & Manufacturing Organizations (CDMOs / CMOs) (2024-2032) ($MN)
  • Table 35 Global Automation in Pharmaceutical Manufacturing Market Outlook, By Research and Academic Institutions (2024-2032) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.